Product Overview
Use of a new improvised therapeutic antibody to form novel medicines for the treatment of different diseases includes next-generation antibody therapeutics. Next-generation antibody therapeutics have been clinically developed for many diseases by pharmaceutical and biotechnology firms.
Get Free Sample Report: https://www.wiseguyreports.com/sample-request/6136715-global-next-generation-antibody-therapeutics-market-outlook-2030
Global Next-Generation Antibody Therapeutics Market: Key Players
- Bristol-Myers Squibb
o Company Overview
o Business Strategy
o Key Product Offerings
o Financial Performance
o Key Performance Indicators
o Risk Analysis
o Recent Development
o Regional Presence
o SWOT Analysis
- Pfizer
- Roche
- Bristol-Myers Squibb
- Amgen
- AstraZeneca
- Bayer
- Takeda Pharmaceuticals
- Biogen
- Seattle Genetics
- ImmunoGen
- Kyowa Hakko Kirin
- Xencor
- Dyax Corp
Market Highlights
Global Next-Generation Antibody Therapeutics Market: Segments
Global Next Generation Antibody Therapeutics Market is segmented by therapeutic area into oncology and autoimmune/inflammatory. The greater market share in 2019 was accounted for by the oncology segment and is expected to see the highest growth during the forecast period due to rising incidence of cancer globally. The key factors for market growth are the growing prevalence of cancer worldwide, where next generation antibodies serve as the predominant therapy and new product launches.
Global Next Generation Antibody Therapeutics Market: Market Dynamics
Drivers
Increasing investments in healthcare infrastructural development
During the forecast period, the global next-generation demand for antibody therapeutics is likely to expand at a significant rate. This is largely due to the success of antibody therapeutics for chronic conditions such as cancer and autoimmune diseases of the next generation. Generally speaking, antibody therapeutics have experienced clear scientific developments to improve their effectiveness.
View Detailed Report: https://www.wiseguyreports.com/reports/6136715-global-next-generation-antibody-therapeutics-market-outlook-2030
Restraints
High cost involved in research and development for developing next generation antibodies
Different governments have implemented numerous stringent rules and regulations relating to the use of antibodies, which are significantly hampering the global demand for next-generation antibody therapeutics. In addition, the high investment required for R&D activities and the preference among medical and healthcare professionals as well as patients for older-generation drug therapies are some of the major issues facing the global market during the forecast period.
Global Next-Generation Antibody Therapeutics Market: Regions
Global next generation antibody therapeutics market is segmented based on regional analysis into five major regions. These include North America, Latin America, Europe, APAC and MENA.
Global next generation antibody therapeutics market in North America held the largest market share of in the year 2019 and due to growing R&D activities, technical advancements in antibody therapies, growing healthcare expenditure and increasing government initiatives in this area, growth over the forecast period is expected to be sustained. In addition, the growth of the market is also driven by the growing prevalence of chronic diseases and by the growing approval of new medicines. It is anticipated that the growing occurrence of multiple diseases, growing advances in therapeutic antibodies, evolving antibody technologies, rising demand for better healthcare services, and rapid growth in biosimilar antibodies and engineered antibodies will bring new opportunities for the region’s next-generation therapeutic antibody industry.
For Any Query: https://www.wiseguyreports.com/enquiry/6136715-global-next-generation-antibody-therapeutics-market-outlook-2030
Global Next-Generation Antibody Therapeutics Market: Recent Development
- In June 2019, Xencor has initiated first dose in patient in a phase I clinical trial for XmAb22841, a bispecific antibody that targets CTLA-4 and LAG-3 receptor inhibitors for the treatment of advanced solid tumors. If successful, it will change the treatment landscape of patients suffering from advanced solid tumors throughout the world
Global Next-Generation Antibody Therapeutics Market report also contains analysis on:
Global next-generation antibody therapeutics market Segments:
- By Therapeutic Area:
- Oncology
- Autoimmune/Inflammatory
- By Technology:
- Antibody-Drug Conjugates (ADCs)
- Bispecific Antibodies
- Fc-engineered Antibodies
- Antibody Fragments and Antibody-like Proteins
- Biosimilar Antibody Products
- Next-generation antibody therapeutics Market Dynamics
- Next-generation antibody therapeutics Market Size
- Supply & Demand
- Current Trends/Issues/Challenges
- Competition & Companies Involved in the Market
- Value Chain of the Market
- Market Drivers and Restraints
Table of Content
- Executive Summary
- Global Next Generation Antibody Therapeutics Market
- Research Methodology
- Average Pricing Analysis
- Macro-Economic Indicators
- Market Dynamics
- Correlation & Regression Analysis
- Recent Development, Policies & Regulatory Landscape
- Risk Analysis
- Global Next Generation Antibody Therapeutics Market Analysis
- Global Next Generation Antibody Therapeutics Market
- Global Next Generation Antibody Therapeutics Market: Market Segmentation
- Company Profile
Read Other Reports from our Database :
About Us:
Wise Guy Reports is part of the Wise Guy Research Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available. We also provide COTS (Commercial off the Shelf) business sector reports as custom exploration agreeing your particular needs.
Contact Us:
Ph: +162 825 80070 (US)
Ph: +44 203 500 2763 (UK)